Mitoxantrone hydrochloride injection for tracing helps to decrease parathyroid gland resection and increase lymph...

Area of Science:

• Oncology
• Surgical Innovation
• Medical Imaging

Background:

• Preserving parathyroid glands (PGs) during thyroid surgery is critical to prevent hypoparathyroidism.
• Current methods for identifying PGs intraoperatively have limitations.
• Accurate lymph node staging is essential for effective thyroid cancer treatment.

Purpose of the Study:

• To evaluate the efficacy and safety of a novel mitoxantrone hydrochloride injection for tracing (MHI) in thyroid cancer surgery.
• To determine if MHI improves the identification and preservation of parathyroid glands.
• To assess MHI's impact on the detection rate of central compartment lymph nodes.

Main Methods:

• An open-label, multicenter, randomized clinical trial (CTR20171137) involving 461 patients with thyroid carcinoma.
• Patients underwent total thyroidectomy and bilateral central compartment lymph node dissection.
• Randomization to either the MHI group or a control group.

Main Results:

• The parathyroid gland resection rate was significantly lower in the MHI group (6.6%) compared to the control group (26.6%) (P < 0.001).
• MHI successfully stained central lymph nodes in 90.5%±12.0% of cases.
• The MHI group detected more lymph nodes per patient (13.0±7.3) than the control group (10.1±6.4) (P < 0.001).
• No adverse events related to MHI were reported.

Conclusions:

• Mitoxantrone hydrochloride injection for tracing (MHI) is a safe and effective tracer for thyroid cancer surgery.
• MHI significantly aids in the preservation of parathyroid glands.
• MHI enhances the detection of central lymph nodes, potentially improving cancer staging.